Synopsis
The shocking true investigation behind Nathan Fielder's You Can See Everything and The Dropout, from the award-winning journalist who first broke the story. Bad Blood details the breathtaking rise and fall of Theranos, the multibillion-dollar biotech startup founded by Elizabeth Holmes.
Winner of the Financial Times/McKinsey Business Book of the Year Award
'A story so incredible you'd think it was fiction' – James Patterson
'A tale of corporate fraud and legal browbeating that reads like a crime thriller' – TIME
Elizabeth Holmes was a brilliant Stanford dropout whose startup ‘unicorn’ Theranos promised to revolutionize the medical industry with a machine that would make blood testing faster and easier. Backed by wealthy investors, Theranos sold shares that valued the company at more than $9 billion.
There was just one problem.
The technology didn’t work.
Despite threats of legal action, brave whistleblowers started to talk. They revealed a culture of intimidation and secrecy, technology that repeatedly failed, results sent to real patients that were incorrect but upon which life-changing medical decisions were being made, with devastating consequences.
More relevant than ever, this is an utterly gripping tale of ambition and scandal set amid the bold promises of Silicon Valley.
Details
Reviews
“I couldn’t put down this thriller with a tragic ending . . . a book so compelling that I couldn’t turn away . . . This book has everything: elaborate scams, corporate intrigue, magazine cover stories, ruined family relationships, and the demise of a company once valued at nearly $10 billion”Bill Gates, '5 books I loved in 2018'
“In this Silicon Valley drama, he opens his reporter’s notebook to deliver a tale of corporate fraud and legal browbeating that reads like a crime thriller.”The 10 Best Nonfiction Books of the Year, TIME
“Riveting . . . a blistering critique of Silicon Valley . . . The real heroes, though, are his sources: the young scientists who worked at the company and risked their reputations and careers by voicing their concerns. Were it not for their courage, Theranos might still be testing blood today”David Crow, Financial Times
“A beautifully controlled narrative that challenges the gold-rush mentality of Silicon Valley.”Lionel Barber, Editor of the FT, 'Books of the Year', Financial Times
